NASDAQ:CNSTConstellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CNST shares have decreased by 21.2% and is now trading at $25.68.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Constellation Pharmaceuticals.

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Constellation Pharmaceuticals.

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its earnings results on Wednesday, August, 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.06.
View Constellation Pharmaceuticals' earnings history.

9 brokerages have issued twelve-month price objectives for Constellation Pharmaceuticals' stock. Their forecasts range from $28.00 to $75.00. On average, they expect Constellation Pharmaceuticals' share price to reach $48.25 in the next year. This suggests a possible upside of 87.9% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals.

Media stories about CNST stock have been trending very positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a news impact score of 4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Constellation Pharmaceuticals.

Some companies that are related to Constellation Pharmaceuticals include Schrodinger (SDGR), Legend Biotech (LEGN), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Evotec (EVTCY), GW Pharmaceuticals PLC- (GWPH), HYPERA S A/S (HYPMY), Allakos (ALLK), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Opko Health (OPK), Arena Pharmaceuticals (ARNA) and Biohaven Pharmaceutical (BHVN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Axsome Therapeutics (AXSM), AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Crispr Therapeutics (CRSP), Enphase Energy (ENPH), Novavax (NVAX), NVIDIA (NVDA) and Provention Bio (PRVB).

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Regents of The University of California (2.95%), Victory Capital Management Inc. (1.82%), Jennison Associates LLC (1.58%), Candriam Luxembourg S.C.A. (0.94%), P.A.W. Capital Corp (0.15%) and Swiss National Bank (0.14%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, P.A.W. Capital Corp, Alps Advisors Inc., and Strs Ohio. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents, and Patrick Trojer.
View insider buying and selling activity for Constellation Pharmaceuticals.

CNST stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Candriam Luxembourg S.C.A., Victory Capital Management Inc., Swiss National Bank, Rafferty Asset Management LLC, SG Americas Securities LLC, New York State Common Retirement Fund, and State Board of Administration of Florida Retirement System. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $25.68.

Constellation Pharmaceuticals has a market capitalization of $1.22 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]